Mirae Asset Global Investments Co. Ltd. Boosts Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA)

Mirae Asset Global Investments Co. Ltd. increased its stake in Vera Therapeutics, Inc. (NASDAQ:VERA) by 12.3% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 23,116 shares of the company’s stock after buying an additional 2,537 shares during the period. Mirae Asset Global Investments Co. Ltd. owned 0.05% of Vera Therapeutics worth $356,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in Vera Therapeutics by 9.3% in the 3rd quarter. Vanguard Group Inc. now owns 1,574,390 shares of the company’s stock valued at $21,585,000 after acquiring an additional 134,125 shares in the last quarter. Barclays PLC lifted its position in Vera Therapeutics by 964.6% in the 3rd quarter. Barclays PLC now owns 71,703 shares of the company’s stock valued at $983,000 after acquiring an additional 64,968 shares in the last quarter. Swiss National Bank bought a new position in Vera Therapeutics in the 3rd quarter valued at approximately $668,000. Rafferty Asset Management LLC bought a new position in Vera Therapeutics in the 3rd quarter valued at approximately $1,870,000. Finally, Citigroup Inc. lifted its position in Vera Therapeutics by 470.0% in the 3rd quarter. Citigroup Inc. now owns 57,390 shares of the company’s stock valued at $787,000 after acquiring an additional 47,322 shares in the last quarter. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Insider Buying and Selling

In other Vera Therapeutics news, Director Maha Katabi purchased 161,290 shares of the business’s stock in a transaction on Tuesday, January 30th. The stock was acquired at an average price of $31.00 per share, for a total transaction of $4,999,990.00. Following the purchase, the director now owns 3,628,446 shares of the company’s stock, valued at approximately $112,481,826. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Vera Therapeutics news, SVP Joseph R. Young sold 5,714 shares of the stock in a transaction on Wednesday, April 10th. The stock was sold at an average price of $40.00, for a total value of $228,560.00. Following the completion of the sale, the senior vice president now owns 53,171 shares in the company, valued at approximately $2,126,840. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Maha Katabi purchased 161,290 shares of the business’s stock in a transaction on Tuesday, January 30th. The stock was acquired at an average price of $31.00 per share, with a total value of $4,999,990.00. Following the purchase, the director now directly owns 3,628,446 shares in the company, valued at approximately $112,481,826. The disclosure for this purchase can be found here. In the last three months, insiders have sold 526,551 shares of company stock valued at $21,533,345. 21.70% of the stock is owned by company insiders.

Vera Therapeutics Price Performance

Shares of Vera Therapeutics stock opened at $39.65 on Friday. Vera Therapeutics, Inc. has a one year low of $6.07 and a one year high of $50.78. The stock’s fifty day moving average is $43.12 and its 200 day moving average is $26.95. The stock has a market cap of $2.16 billion, a P/E ratio of -17.31 and a beta of 1.05. The company has a debt-to-equity ratio of 0.49, a quick ratio of 7.71 and a current ratio of 7.71.

Vera Therapeutics (NASDAQ:VERA) last announced its earnings results on Wednesday, March 20th. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.05). Sell-side analysts anticipate that Vera Therapeutics, Inc. will post -2.18 earnings per share for the current year.

Wall Street Analysts Forecast Growth

VERA has been the topic of several research analyst reports. Wedbush increased their price target on Vera Therapeutics from $21.00 to $34.00 and gave the company a “neutral” rating in a report on Thursday, March 21st. Raymond James raised Vera Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their price target for the company from $29.00 to $37.00 in a report on Friday, January 26th. Cantor Fitzgerald initiated coverage on Vera Therapeutics in a report on Monday, January 8th. They set an “overweight” rating on the stock. Oppenheimer initiated coverage on Vera Therapeutics in a report on Thursday, January 25th. They set an “outperform” rating and a $26.00 price target on the stock. Finally, Guggenheim reissued a “buy” rating and set a $56.00 price target on shares of Vera Therapeutics in a report on Friday, April 5th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Vera Therapeutics has a consensus rating of “Buy” and a consensus price target of $32.29.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.